Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Zoom Video Communications, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Zoom Video Communications, Inc. trades at $94.07 (market cap $28.64B). The key difference: Zoom Video Communications, Inc. is far larger — about 10× Dyne Therapeutics Inc. Common Stock's market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Zoom Video Communications, Inc. for 92 Days on average.
| DYN | ZM | |
|---|---|---|
Market Cap | $2.86B | $28.64B |
Volume | 3,341,579 | 2,595,677 |
Sector | Health | Technology |
52-Week High | $26.78 | $111.88 |
52-Week Low | $14.60 | $72.72 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $2.18B | $21.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Zoom Communications (ZM) trades at $94.47, down 3.54% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $118.08. The company reported strong profitability with a net income margin of 65.19% in 2026 and is advancing its AI-powered revenue OS, positioning for growth amid recent earnings beats.
The stock presents a compelling opportunity given its attractive valuation (P/E of 9.11) and robust fundamentals, though risks include reliance on international sales and competitive pressures in the communication software sector. Upside potential exists if the company executes on its AI initiatives and maintains earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
